WO1998019555A1 - Fat with specific antisclerosis effects - Google Patents
Fat with specific antisclerosis effects Download PDFInfo
- Publication number
- WO1998019555A1 WO1998019555A1 PCT/CZ1997/000038 CZ9700038W WO9819555A1 WO 1998019555 A1 WO1998019555 A1 WO 1998019555A1 CZ 9700038 W CZ9700038 W CZ 9700038W WO 9819555 A1 WO9819555 A1 WO 9819555A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- units
- weight
- fat
- cholesterol
- vitamin
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 7
- 235000019197 fats Nutrition 0.000 claims abstract description 75
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 38
- 239000000654 additive Substances 0.000 claims abstract description 14
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract description 11
- 235000019160 vitamin B3 Nutrition 0.000 claims abstract description 11
- 239000011708 vitamin B3 Substances 0.000 claims abstract description 11
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 10
- 239000003921 oil Substances 0.000 claims abstract description 10
- 235000019198 oils Nutrition 0.000 claims abstract description 10
- 239000008280 blood Substances 0.000 claims abstract description 9
- 210000004369 blood Anatomy 0.000 claims abstract description 9
- 235000019737 Animal fat Nutrition 0.000 claims abstract description 8
- 235000013311 vegetables Nutrition 0.000 claims abstract description 8
- 230000007423 decrease Effects 0.000 claims abstract description 7
- 235000013310 margarine Nutrition 0.000 claims abstract description 7
- 230000000996 additive effect Effects 0.000 claims abstract description 6
- 235000014121 butter Nutrition 0.000 claims abstract description 6
- 239000003264 margarine Substances 0.000 claims abstract description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 5
- 239000008158 vegetable oil Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000003995 emulsifying agent Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 239000001828 Gelatine Substances 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 4
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical class O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 235000019871 vegetable fat Nutrition 0.000 claims 3
- 230000000055 hyoplipidemic effect Effects 0.000 abstract description 6
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 58
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 8
- 229940075554 sorbate Drugs 0.000 description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
- 229930003427 Vitamin E Natural products 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 239000011719 vitamin A Substances 0.000 description 5
- 235000019155 vitamin A Nutrition 0.000 description 5
- 229940045997 vitamin a Drugs 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 235000002378 plant sterols Nutrition 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000002930 anti-sclerotic effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/015—Reducing calorie content; Reducing fat content, e.g. "halvarines"
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
Definitions
- This invention relates to fat with specific antisclerosis effects, especially to consumed fat, margarine, halvarine or vegetable butter, containing on partly at least 25 percent basic fat phase, which consists of oil and/or hardened vegetable oil and possibly an additional animal fat, and partly containing the additives which decreases cholesterol level and/or reduces the development of cholesterol in the blood.
- hyperhpoproteinemie One of the basic factors affecting the incidence of diseases involving atherosclerosis is hyperhpoproteinemie. It has been recently found that up to 90 percent of population is showing signs of cholesterol increase in the blood, especially LDL cholesterol.
- chemotherapeutic treatment using hypolipidemics that then directly affects the area of synthesis of cholesterol or LDL cholesterol during metabolic proceses.
- the said chemotherapeutics are applied according to the medical prescription combined or not with other supporting substances such as vitamins e.g. vitamin A, vitamin B,E.
- the shortcomming of the said application of hypolipidemics is, that they are used after the high level of cholesterol has already caused health problems. In addition it is necessary to these substances in relatively high doses and under dostor's supervision.
- the purpose of the invention is to prevent hypercholesterolemy by spreading the above said hypolipidemics widely among the population so as to avoid their consequential medical prescription.
- This purpose solved the subject-matter of the invention, which is a fat with specific antisclerosis effects, especially to consumed fat, margarine, halvarine or vegetable butter, containing partly at least 25 percent basic fat phase, which consists of oil and/or hardened vegetable oil and possibly an additional animal fat, partly the additive which decreases cholesterol level and/or reduces the development of cholesterol in the blood.
- the nature of this invention is, that the additive which decreases cholesterol level and/or reduces the development of cholesterol in the blood is created by hypolipidemics from a group of essential phosphoUpides and/or vitamin PP, alternative by its derivates and/or by statins.
- fat mixture of 1.000 units of weight contains 250 to 995 units of weight of fat phase, up to 4,5 units of weight of hypolipidemics and up to 12,5 units of weight of additives, with the reminder being completed of water.
- fat mixture of 1.000 units of weight contains 250 to 995 units of weight of fat phase, 0,5 to 20 units weight of essential phosphoUpides, up to 5 units of weight of other vitamins, up to 40 units of weight of emulgators and up to 5,9 units of weight of other additives, with the reminder being completed of water, or that fat mixture of 1.000 units of weight contains 250 to 995 units of weight of fat phase, 0,5 to 20 units of weight of vitamin PP or its derivates, up to 5 units of weight of other vitamins, up to 40 units of weight of emulgators, up to 40 units of weight of gelatine and/or modified starches and/or pectines, up to 17 units of weight of other additives, with the reminder being completed of water, or finaly that fat mixture of 1.000 units of weight contains 250 to 995 units of weight of fat phase, 0,1 to 5 units of weight of statins, up to 5 units of weight of other vitamins, up to 5 units of weight of flavourings, up to 40 units of weight of
- the advantage of the appUed substances from a group of hypoUpidemics according to the invention is, that its defined substances form organic part in the consumed fats, margarines, halvarines or vegetable butters and are through the mediation of them appUed in a small and at the same time unharmful or supportive quantitives consumed in common fats and foods in the course of the day, that contain such fats.
- Another considerable advantage of the fats consisted according to the invention is, that they mosty forms water/fat or fat/water emulsion, which are not commonly used for high tempetature preparing of other foods and therefore they are not exposed to such temperature changes, that could deteriorate additives.
- the basic fat component according to the invention mentioned in the following examples is formed by liquid and/or hardened vegetable oU such as rapessed oil, sunflower oil, soybean oil, palm oil or palmolein, or its combinations and alternati- velly with other vegetable oils, that are made of products of vegetable origin by analogic technical processing by pressing and/or extracting. It is possible to add a little animal fat, formed mainly of milk fat, liquid or hardened fat or tallow, to said mixture. Optionally, those components, or sam of them, could be replaced by analogic animal fats without effects to the invention.
- liquid and/or hardened vegetable oU such as rapessed oil, sunflower oil, soybean oil, palm oil or palmolein, or its combinations and alternati- velly with other vegetable oils, that are made of products of vegetable origin by analogic technical processing by pressing and/or extracting. It is possible to add a little animal fat, formed mainly of milk fat, liquid or hardened fat or tallow, to said mixture. Optionally, those components, or
- the basic fat phase applied in the foUowing examples is illustrated in the following types:
- the examplatory types of structure of fat phases are indicated by letters A to D, that correspond with the mixture mentioned above to simplify the following examples.
- the basic fat phase be enriched by the fat and/or by water soluble form of particular hypoUpidemics according to the invention, or its combination.
- Example 1 Fat of which 1000 g contains
- Example 2 Fat of which 1000 g contains
- Example 3 Fat of which 1000 g contains
- Example 4 Fat of which 1000 g contains
- Example 6 Fat of which 1000 g contains 400 g of fat phase type B 10 g of essential phosphoUpides 10 g of emulgators 10 g of salt 0,5 g of kalium sorbate 0,5 g of vitamin E 0,1 g of vitamin A 568,9 g of water
- Example 7 Fat of which 1000 g contains 995 g of fat phase type D 5 g of vitamin PP and/or its derivates
- Example 8 Fat of which 1000 g contains
- Example 9 Fat of which 1000 g contains
- Example 10 Fat of which 1000 g contains
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Edible Oils And Fats (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL97327668A PL327668A1 (en) | 1996-11-07 | 1997-10-30 | Fat having specific antisclerotic effect |
| EA199800624A EA199800624A1 (ru) | 1996-11-07 | 1997-10-30 | Жир со специфическим противосклеротическим воздействием |
| EE9800212A EE9800212A (et) | 1996-11-07 | 1997-10-30 | Spetsiifilise antisklerootilise toimega rasvaine |
| EP97909116A EP0918466A1 (en) | 1996-11-07 | 1997-10-30 | Fat with specific antisclerosis effects |
| SK930-98A SK93098A3 (en) | 1996-11-07 | 1997-10-30 | Fat with specific antisclerosis effects |
| LVP-98-156A LV12174B (en) | 1996-11-07 | 1998-07-27 | FATS WITH SPECIFIC ANTI-CELLULOTIC EFFECTS |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ963268A CZ326896A3 (cs) | 1996-11-07 | 1996-11-07 | Tuk se specifickými protisklerotickými účinky |
| CZPV3268-96 | 1996-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998019555A1 true WO1998019555A1 (en) | 1998-05-14 |
Family
ID=5466435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CZ1997/000038 WO1998019555A1 (en) | 1996-11-07 | 1997-10-30 | Fat with specific antisclerosis effects |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0918466A1 (cs) |
| CZ (1) | CZ326896A3 (cs) |
| EA (1) | EA199800624A1 (cs) |
| EE (1) | EE9800212A (cs) |
| HU (1) | HUP0001100A3 (cs) |
| LT (1) | LT4528B (cs) |
| LV (1) | LV12174B (cs) |
| PL (1) | PL327668A1 (cs) |
| SK (1) | SK93098A3 (cs) |
| WO (1) | WO1998019555A1 (cs) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4734B (lt) | 2000-01-21 | 2000-11-27 | Alfridas Putramentas | Aliejų kompozicija |
| WO2002064809A3 (en) * | 2001-02-09 | 2003-04-24 | Unilever Nv | Process for the preparation of one or more statins by fermentation |
| WO2005104864A1 (en) * | 2004-04-28 | 2005-11-10 | Unilever N.V. | Edible oil containing statins |
| WO2006021293A1 (en) * | 2004-08-23 | 2006-03-02 | Unilever N.V. | Composition comprising statin |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2133508A1 (en) * | 1971-04-15 | 1972-12-01 | Inst Biochimie | 4-thiazolidinecarboxylic acid derivs - with in vivo thiol liberating activity |
| DE2607654A1 (de) * | 1975-03-05 | 1976-09-16 | Hoffmann La Roche | Vitaminierungsverfahren |
| FR2466459A1 (fr) * | 1979-10-05 | 1981-04-10 | Fabre Sa Pierre | Esters phenoxy isobutyriques d'hydroxy nicotinamides et leurs sels, leur procede de preparation et leur application en therapeutique |
| RO81579A2 (ro) * | 1981-01-20 | 1983-04-29 | Intreprinderea De Medicamente "Biofarm",Ro | Granule cu efect hepatoprotector hipocolesterolemiant si reconfortantgeneral |
| EP0148303A1 (de) * | 1984-01-11 | 1985-07-17 | von Mletzko, Armin, Dr. | Diätetikum |
| FR2704556A1 (fr) * | 1993-04-30 | 1994-11-04 | Rhone Poulenc Rorer Sa | Virus recombinants et leur utilisation en thérapie génique. |
| WO1996034855A1 (en) * | 1995-05-01 | 1996-11-07 | Scotia Holdings Plc | Fatty acid esters as bioactive compounds |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2708633B2 (ja) | 1991-05-03 | 1998-02-04 | ライシオン テータート オサケユイチア アクティエボラーグ | 血清における高コレステロールレベルを低めるための物質及びその物質を調製するための方法 |
-
1996
- 1996-11-07 CZ CZ963268A patent/CZ326896A3/cs unknown
-
1997
- 1997-10-30 EA EA199800624A patent/EA199800624A1/ru unknown
- 1997-10-30 SK SK930-98A patent/SK93098A3/sk unknown
- 1997-10-30 PL PL97327668A patent/PL327668A1/xx unknown
- 1997-10-30 EP EP97909116A patent/EP0918466A1/en not_active Withdrawn
- 1997-10-30 HU HU0001100A patent/HUP0001100A3/hu unknown
- 1997-10-30 WO PCT/CZ1997/000038 patent/WO1998019555A1/en not_active Application Discontinuation
- 1997-10-30 EE EE9800212A patent/EE9800212A/xx unknown
-
1998
- 1998-07-23 LT LT98-096A patent/LT4528B/lt not_active IP Right Cessation
- 1998-07-27 LV LVP-98-156A patent/LV12174B/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2133508A1 (en) * | 1971-04-15 | 1972-12-01 | Inst Biochimie | 4-thiazolidinecarboxylic acid derivs - with in vivo thiol liberating activity |
| DE2607654A1 (de) * | 1975-03-05 | 1976-09-16 | Hoffmann La Roche | Vitaminierungsverfahren |
| FR2466459A1 (fr) * | 1979-10-05 | 1981-04-10 | Fabre Sa Pierre | Esters phenoxy isobutyriques d'hydroxy nicotinamides et leurs sels, leur procede de preparation et leur application en therapeutique |
| RO81579A2 (ro) * | 1981-01-20 | 1983-04-29 | Intreprinderea De Medicamente "Biofarm",Ro | Granule cu efect hepatoprotector hipocolesterolemiant si reconfortantgeneral |
| EP0148303A1 (de) * | 1984-01-11 | 1985-07-17 | von Mletzko, Armin, Dr. | Diätetikum |
| FR2704556A1 (fr) * | 1993-04-30 | 1994-11-04 | Rhone Poulenc Rorer Sa | Virus recombinants et leur utilisation en thérapie génique. |
| WO1996034855A1 (en) * | 1995-05-01 | 1996-11-07 | Scotia Holdings Plc | Fatty acid esters as bioactive compounds |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE WPI Section Ch Week 8350, Derwent World Patents Index; Class A96, AN 83-842468, XP002056772 * |
| H. GYLLING ET AL.: "Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men", JOURNAL OF LIPID RESEARCH, vol. 37, no. 8, 1996, pages 1776 - 1785, XP002056770 * |
| L. ROZEWICKA ET AL.: "Effect of essential phospholipids on the lipid content in the liver and myocardium of rats fed a high-fat diet", FOLIA BIOLOGICA, vol. 26, no. 4, 1978, KRAKOW, POLAND, pages 249 - 255, XP002056771 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4734B (lt) | 2000-01-21 | 2000-11-27 | Alfridas Putramentas | Aliejų kompozicija |
| WO2002064809A3 (en) * | 2001-02-09 | 2003-04-24 | Unilever Nv | Process for the preparation of one or more statins by fermentation |
| WO2005104864A1 (en) * | 2004-04-28 | 2005-11-10 | Unilever N.V. | Edible oil containing statins |
| WO2006021293A1 (en) * | 2004-08-23 | 2006-03-02 | Unilever N.V. | Composition comprising statin |
Also Published As
| Publication number | Publication date |
|---|---|
| LV12174B (en) | 1999-05-20 |
| LT98096A (en) | 1999-02-25 |
| LV12174A (lv) | 1998-12-20 |
| EA199800624A1 (ru) | 1998-12-24 |
| LT4528B (lt) | 1999-07-26 |
| PL327668A1 (en) | 1998-12-21 |
| CZ326896A3 (cs) | 1998-05-13 |
| SK93098A3 (en) | 1999-01-11 |
| HUP0001100A3 (en) | 2001-02-28 |
| EE9800212A (et) | 1998-12-15 |
| EP0918466A1 (en) | 1999-06-02 |
| HUP0001100A2 (hu) | 2000-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stortz et al. | Edible oleogels in food products to help maximize health benefits and improve nutritional profiles | |
| McKevith | Nutritional aspects of oilseeds | |
| US8524309B2 (en) | Oil or fat composition | |
| Kolanowski et al. | Enrichment of food products with polyunsaturated fatty acids by fish oil addition | |
| Kris-Etherton et al. | Dietary stearic acid and risk of cardiovascular disease: intake, sources, digestion, and absorption | |
| CA2418350C (en) | Oil/fat composition | |
| DE69629502T2 (de) | Fettenthaltende Nahrungsmittelprodukte | |
| CN101505609B (zh) | 油脂组合物 | |
| WO2003024237A1 (en) | Oil composition | |
| Punita et al. | Effect of feeding crude red palm oil (Elaeis guineensis) and grain amaranth (Amaranthus paniculatus) to hens on total lipids, cholesterol, PUFA levels and acceptability of eggs | |
| Choudhary et al. | Palm (Elaeis guineensis jacq.) oil | |
| Tereshchuk | Theoretical and practical aspects of the development of a balanced lipid complex of fat compositions | |
| JP5100974B2 (ja) | 油脂組成物 | |
| DE60132664T2 (de) | Natürliches pflanzenöl mit angereichertem unverseifbarem anteil als nahrungsmittelbestandteil | |
| EP0918466A1 (en) | Fat with specific antisclerosis effects | |
| Han et al. | Plant-based oils | |
| JPH10313797A (ja) | 家禽用飼料および家禽卵の生産方法 | |
| JP2005126405A (ja) | 肥満防止剤 | |
| CN104413147A (zh) | 一种用于配方奶粉的油脂组合物、其制备方法及其用途 | |
| Cofrades et al. | Potential of fatty components in the valorization of foods by means of health claims | |
| PÉREZ‐GRANADOS et al. | Calcium absorption in rats consuming olive oil or sunflower oil unused or used in frying | |
| RU2708552C1 (ru) | Масложировой продукт для функционального питания | |
| Hopland | Short term effect of omega-3 products on biomarkers of oxidative stress in healthy volunteers: a randomized controlled trial | |
| Borher et al. | α-and γ-tocopherol levels in Nelore steer blood plasma after a single oral treatment of soybean oil deodorizer distillate (SODD) | |
| Pérez‐Granados et al. | Intake of unused palm olein and palm olein used in frying does not affect calcium and phosphorus bioavailability in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): EE HU LT LV PL SK UA AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 93098 Country of ref document: SK |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 98-096 Country of ref document: LT |
|
| ENP | Entry into the national phase |
Ref document number: 1998 980156 Country of ref document: LV Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1998980156 Country of ref document: LV |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1997909116 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 199800624 Country of ref document: EA |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWP | Wipo information: published in national office |
Ref document number: 98-096 Country of ref document: LT |
|
| WWP | Wipo information: published in national office |
Ref document number: 1997909116 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 98-096 Country of ref document: LT |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 98-096 Country of ref document: LT |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1997909116 Country of ref document: EP |